Skip to main content

Table 3 Baseline features of the participants

From: Efficacy and safety of adding rivaroxaban to the anti-platelet regimen in patients with coronary artery disease: a systematic review and meta-analysis of randomized controlled trials

Trials

Age (years)

Males (%)

HT (%)

Ds (%)

DM (%)

Cs (%)

 

R/placebo

R/placebo

R/placebo

R/placebo

R/placebo

R/placebo

ATLAS-ACS 2 TIMI 51

61.9/61.5

74.6/75.0

67.4/67.5

48.7/48.2

32.1/31.8

–

GEMINI-ACS-1

62.0/63.0

75.0/75.0

71.0/75.0

56.0/56.0

29.0/30.0

32.0/34.0

COMPASS

68.3/68.2

67.5/68.2

75.5/75.4

–

37.7/38.1

3.80/3.70

ATLAS-ACS-TIMI 46

57.2/57.8

77.6/76.3

57.4/56.9

44.4/43.6

19.4/19.1

61.9/62.6

  1. R rivaroxaban group, HT hypertension, Ds dyslipidemia, DM diabetes mellitus, Cs current smoker
Back to article page

BMC Pharmacology and Toxicology

ISSN: 2050-6511

Contact us